An international randomized multicenter comparison of nasal potential difference techniques

Chest

Volumn 138, Issue 4, 2010, Pages 919-928

  Solomon, George M ^a   Konstan, Michael W ^b   Wilschanski, Michael ^c   Billings, Joanne ^d   Sermet Gaudelus, Isabelle ^e   Accurso, Frank ^f   Vermeulen, François ^g   Levin, Elina ^a   Hathorne, Heather ^a   Reeves, Ginger ^a   Sabbatini, Gina ^a   Hill, Aubrey ^a   Mayer Hamblett, Nicole ^h   Ashlock, Melissa ⁱ   Clancy, John Paul ^a   Rowe, Steven M ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d UNIVERSITY OF MINNESOTA   (United States)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

^f UNIVERSITY OF COLORADO   (United States)

^g UNIVERSITY OF LEUVEN   (Belgium)

^h UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

ⁱ Cystic Fibrosis Foundation Therapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; AMILORIDE; ISOPRENALINE; RINGER SOLUTION; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ADULT; ARTICLE; ARTIFACT; CATHETER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIAGNOSTIC TEST; FEMALE; HUMAN; HYPERPOLARIZATION; INTERMETHOD COMPARISON; MALE; MULTICENTER STUDY; NASAL POTENTIAL DIFFERENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELIABILITY; SODIUM CONDUCTANCE; TECHNIQUE;

EID: 77957827856     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.10-0179     Document Type: Article

References (25)

1. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med. 2005;352(19):1992-2001.
2. Knowles M, Gatzy J, Boucher R. Increased bioelectric potential difference across respiratory epithelia in cystic fibrosis. N Engl J Med. 1981;305(25):1489-1495. (Pubitemid 12244203)
3. Knowles M, Gatzy J, Boucher R. Relative ion permeability of normal and cystic fibrosis nasal epithelium. J Clin Invest. 1983;71(5):1410-1417. (Pubitemid 13098931)
4. Mayell SJ, Munck A, Craig JV, et al; European Cystic Fibrosis Society Neonatal Screening Working Group. A European consensus for the evaluation and management of infants with an equivocal diagnosis following newborn screening for cystic fibrosis. J Cyst Fibros. 2009;8(1):71-78.
5. Rosenstein BJ, Cutting GR; Cystic Fibrosis Foundation Consensus Panel. The diagnosis of cystic fibrosis: a consensus statement. J Pediatr. 1998;132(4):589-595.
6. Goubau C, Wilschanski M, Skalická V, et al. Phenotypic characterisation of patients with intermediate sweat chloride values: towards validation of the European diagnostic algorithm for cystic fibrosis. Thorax. 2009;64(8):683-691.
7. Noone PG, Hohneker KW, Zhou Z, et al. Safety and biological efficacy of a lipid-CFTR complex for gene transfer in the nasal epithelium of adult patients with cystic fibrosis. Mol Ther. 2000;1(1):105-114.
8. Kerem E, Hirawat S, Armoni S, et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet. 2008;372(9640):719-727.
9. Wilschanski M, Yahav Y, Yaacov Y, et al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med. 2003;349(15):1433-1441.
10. Clancy JP, Rowe SM, Bebok Z, et al. No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations. Am J Respir Cell Mol Biol. 2007;37(1):57-66.
11. Clancy JP, Rowe SM, Durie P, et al. NPD evaluation of ion transport with a CFTR potentiator. Pediatric Pulm Supp. 2009;44:Abstract 222.
12. Konstan MW, Davis PB, Wagener JS, et al. Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution. Hum Gene Ther. 2004;15(12):1255-1269.
13. Yaakov Y, Kerem E, Yahav Y, et al. Reproducibility of nasal potential difference measurements in cystic fibrosis. Chest. 2007;132(4):1219-1226. (Pubitemid 47620996)
14. Rowe SM, Young H, Reeves G, et al. Refinements in nasal potential difference measurement for multicenter clinical trials. Pediatr Pulmonol Suppl. 2008;43:Abstract 296.
15. Knowles MR, Paradiso AM, Boucher RC. In vivo nasal potential difference: techniques and protocols for assessing efficacy of gene transfer in cystic fibrosis. Hum Gene Ther. 1995;6(4):445-455.
16. Standaert TA, Boitano L, Emerson J, et al. Standardized procedure for measurement of nasal potential difference: an outcome measure in multicenter cystic fibrosis clinical trials. Pediatr Pulmonol. 2004;37(5):385-392.
17. Solomon GM, Young H, Reeves G, et al. Protocol for improved NPD performance for international trials. Am J Respir Crit Care Med. 2009;170:A1792.
18. Solomon GM, Konstan M, Wilschanski M, et al. A standardized protocol for nasal potential difference studies: results of a randomized, international, multi-center comparison between techniques. Ped Pulmonol Suppl. 2009;44:Abstract 215.
19. Rowe SM, Accurso F, Clancy JP. Detection of cystic fibrosis transmembrane conductance regulator activity in early-phase clinical trials. Proc Am Thorac Soc. 2007;4(4):387-398. (Pubitemid 47330876)
20. Middleton PG, Geddes DM, Alton EW. Protocols for in vivo measurement of the ion transport defects in cystic fibrosis nasal epithelium. Eur Respir J. 1994;7(11):2050-2056.
21. Davies MG, Geddes DM, Alton EW. The effect of varying tonicity on nasal epithelial ion transport in cystic fibrosis. Am J Respir Crit Care Med. 2005;171(7):760-763. (Pubitemid 40471147)
22. Alton EW, Middleton PG, Caplen NJ, et al. Non-invasive liposome-mediated gene delivery can correct the ion transport defect in cystic fibrosis mutant mice. Nat Genet. 1993;5(2):135-142.
23. Sermet-Gaudelus I, Renouil M, Fajac A, et al. In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study. BMC Med. 2007;5:5.
24. Ahrens RC, Standaert TA, Launspach J, et al. Use of nasal potential difference and sweat chloride as outcome measures in multicenter clinical trials in subjects with cystic fibrosis. Pediatr Pulmonol. 2002;33(2):142-150.
25. House HH, Middleton PG. Impact of different chloride and glucose solutions on nasal potential difference. Pediatr Pulmonol. 2009;44(7):645-648.